CClinicalTrials.gg
Status unknownNCT04822870Updated Apr 6, 2021

Comparison of Ultrasound-guided Quadratus Lumborum Block and Iliohypogastric/Ilioinguinal Nerve Block for Postoperative Pain Management in Patients Undergoing Cesarean Section

An interventional study of quadratus lumborum block and iliohypogastric/ilioinguinal nerve block in Quadratus Lumborum Block, Iliohypogastric/Ilioinguinal Nerve Block and Cesarean Section, sponsored by Peking University People's Hospital. Status unknown at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-06.

Sponsored by Peking University People's Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to compare the analgesic effect of ultrasound-guided quadratus lumborum block and iliohypogastric/ilioinguinal nerve block for postoperative pain management in patients undergoing cesarean section.

02

Conditions studied

  • Quadratus Lumborum Block
  • Iliohypogastric/Ilioinguinal Nerve Block
  • Cesarean Section

Browse trials for

03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 87 is above the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Peking University People's Hospital is the lead sponsor of 584 studies on the registry; 233 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • singleton pregnancy
  • gestation of at least 37 weeks
  • American Society of Anesthesiologists (ASA) physical status I or II
  • finish Pfannenstiel section under combined spinal and epidural anesthesia

Exclusion criteria

Exclusion Criteria:

  • pruritus existed before the surgery
  • allergic to lidocaine, ropivacaine or dexamethasone
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
87 participants (estimated)

Study arms

  • Experimental
    quadratus lumborum block

    Parturients receive ultrasound-guided quadratus lumborum block as post-operative analgesia.

    Procedure: quadratus lumborum block

  • Experimental
    iliohypogastric/ilioinguinal nerve block

    Parturients receive ultrasound-guided iliohypogastric/ilioinguinal nerve block as post-operative analgesia.

    Procedure: iliohypogastric/ilioinguinal nerve block

  • Active comparator
    epidural analgesia

    Parturients receive epidural morphine via epidural catheter placed during anesthesia as post-operative analgesia.

    Procedure: epidural analgesia

Interventions

  • Procedurequadratus lumborum block

    Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.

  • Procedureiliohypogastric/ilioinguinal nerve block

    Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.

  • Procedureepidural analgesia

    Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.

06

What researchers measure

Primary outcomes

  1. morphine consumption

    Every parturient use a patient-controlled intravenous analgesia pump as supplement for the interventions. The analgesia pump contains morphine and can record morphine consumption. Postoperative use of morphine can reflect analgesic effect.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. morphine consumption

    Every parturient use a patient-controlled intravenous analgesia pump as supplement for the interventions. The analgesia pump contains morphine and can record morphine consumption. Postoperative use of morphine can reflect analgesic effect.

    Time frame: 6 hours postoperatively

  2. morphine consumption

    Every parturient use a patient-controlled intravenous analgesia pump as supplement for the interventions. The analgesia pump contains morphine and can record morphine consumption. Postoperative use of morphine can reflect analgesic effect.

    Time frame: 12 hours postoperatively

  3. morphine consumption

    Every parturient use a patient-controlled intravenous analgesia pump as supplement for the interventions. The analgesia pump contains morphine and can record morphine consumption. Postoperative use of morphine can reflect analgesic effect.

    Time frame: 48 hours postoperatively

  4. pain score

    Use visual analogue scale (VAS) 0-10 to evaluate pain intensity and reflect analgesic effect. 0 refers to completely no pain, 10 refers to the most severe pain she has experienced.

    Time frame: 6 hours postoperatively

  5. pain score

    Use visual analogue scale (VAS) 0-10 to evaluate pain intensity and reflect analgesic effect. 0 refers to completely no pain, 10 refers to the most severe pain she has experienced.

    Time frame: 12 hours postoperatively

  6. pain score

    Use visual analogue scale (VAS) 0-10 to evaluate pain intensity and reflect analgesic effect. 0 refers to completely no pain, 10 refers to the most severe pain she has experienced.

    Time frame: 24 hours postoperatively

  7. pain score

    Use visual analogue scale (VAS) 0-10 to evaluate pain intensity and reflect analgesic effect. 0 refers to completely no pain, 10 refers to the most severe pain she has experienced.

    Time frame: 48 hours postoperatively

  8. effective analgesia time

    Time period between finish the intervention and the first time parturient use the patient-controlled intravenous analgesia pump for analgesia supplement.

    Time frame: 48 hours postoperatively

  9. adverse effect

    Nausea and vomiting, pruritus, oversedation, respiratory depression and urinary retention are considered adverse effects. The incidence and severity are recorded, 1 score refers to mild, 2 scores refers to moderate, 3 scores refers to severe and treatment needed.

    Time frame: 6 hours postoperatively

  10. adverse effect

    Nausea and vomiting, pruritus, oversedation, respiratory depression and urinary retention are considered adverse effects. The incidence and severity are recorded, 1 score refers to mild, 2 scores refers to moderate, 3 scores refers to severe and treatment needed.

    Time frame: 12 hours postoperatively

  11. adverse effect

    Nausea and vomiting, pruritus, oversedation, respiratory depression and urinary retention are considered adverse effects. The incidence and severity are recorded, 1 score refers to mild, 2 scores refers to moderate, 3 scores refers to severe and treatment needed.

    Time frame: 24 hours postoperatively

  12. adverse effect

    Nausea and vomiting, pruritus, oversedation, respiratory depression and urinary retention are considered adverse effects. The incidence and severity are recorded, 1 score refers to mild, 2 scores refers to moderate, 3 scores refers to severe and treatment needed.

    Time frame: 48 hours postoperatively

  13. satisfaction score

    Ask the patient to evaluate satisfaction score using 0-10. 0 refers totally dissatisfied, 10 refers to the most satisfied

    Time frame: 48 hours postoperatively

  14. hospital stay

    The hospitalize length

    Time frame: at discharge assessed up to 10 days

  15. hospitalize cost

    Total cost in this hospitalization

    Time frame: at discharge assessed up to 10 days

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04822870
Lead sponsor
Peking University People's Hospital
Responsible party
Yi Feng, MD (Head of Anesthesiology, Peking University People's Hospital) — Principal investigator
First posted
Mar 30, 2021
Start date
Mar 31, 2021
Primary completion
May 2021 (estimated)
Completion
May 2021 (estimated)
Last update
Apr 6, 2021

Study contacts

Yi Feng, MD
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion